|
PRESS RELEASE
Remedy Pharmaceuticals Appoints Thomas MacAllister as Vice President of Research and Development and General Counsel NEW YORK, New York, March 15, 2016 — Remedy Pharmaceuticals, a privately-held, Phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company appointed Thomas MacAllister as Vice President of Research and Development, and General Counsel. “As we begin preparations for commencement later this year of our Phase 3 clinical trial in patients with large hemispheric stroke, Tom’s wealth of CNS-related clinical trial experience will be indispensable,” states Sven Jacobson, CEO of Remedy Pharmaceuticals. “We’re therefore delighted to welcome him to the senior management team.” Thomas MacAllister, Ph.D., JD, has over 25 years of experience in business development, preclinical and clinical development, regulatory strategy, intellectual property and commercialization. He has assembled and led a team that took a program for severe traumatic brain injury from concept through the completion of a Phase 3 clinical trial. Prior to joining Remedy Pharmaceuticals, Dr. MacAllister served as the Chief Executive Officer of Argentum Pharmaceuticals, for whom he developed new business models to reduce the cost of drugs to the healthcare system. He also served as Chief Executive Officer and General Counsel at BHR Pharma and Chief Development Officer at Besins Healthcare SA where he was primarily focused on drug development and oversaw research and development and the intellectual property department. He is an attorney licensed to practice law in the Commonwealth of Virginia, the District of Columbia and before the United States Patent & Trademark Office. “I am excited to join the Remedy Pharmaceuticals at this pivotal time,” notes Thomas MacAllister. “I believe that the Company’s lead product, CIRARA, represents a significant opportunity to define the treatment of CNS-related edema, and thus save and improve the lives of countless patients for whom there are currently no effective therapies. I look forward to helping advance this novel compound through clinical development.” ABOUT CIRARA™ CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com
0 Comments
PRESS RELEASE
Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA On A Novel Drug Treatment For CNS-Related Edema NEW YORK, New York, March 4, 2016 — Remedy Pharmaceuticals, a privately-held, pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which took place on March 2, 2016. “Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA™,” states Sven Jacobson, Chief Executive Officer of Remedy Pharmaceuticals. “We are pleased with the FDA’s guidance on our Phase 3 trial design in patients with large hemispheric stroke and we look forward to initiating the study as quickly as possible.” “There is a major unmet medical need to treat CNS-related edema,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “The encouraging data from our Phase 2 studies suggest CIRARA has the potential to reduce mortality and improve functional outcomes for patients with large hemispheric strokes. We’re now one step closer to achieving that goal.” ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ measured phase dosing technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com Investors Lee Roth / Tram Bui, The Ruth Group 646-536-7012 / 646-536-7035 lroth@theruthgroup.com / tbui@theruthgroup.com Media Kirsten Thomas, The Ruth Group 508-280-6592 kthomas@theruthgroup.com |
RSS Feed
|
Copyright © 2021. Remedy Pharmaceuticals, Inc. / Embark Healthcare - All rights reserved.
|
Website by CG Media LLC
|